Somebody had just posted recently about the lack of data for 787....if you saw the press release today it looks very positive. however. like RA, i think the real announcement we're all waiting for is who might partner with vertex on these programs which are just too big for vertex to go alone. J&J partnered on incivek so they might be a good bet.
"People in this dose group experienced influenza-like symptoms for a median of 1.9 days, compared to 3.7 days in the placebo group. In addition, 93 percent of people in this dose group showed no clinical symptoms of influenza after three days of treatment, compared to 41 percent of people in the placebo group. In this study, VX-787 was generally well-tolerated, with no adverse events leading to discontinuation"
it's still exploratory but ready to move forward (versus being canceled) so that's positive. reducing flu duration by 50% would be pretty popular no? it's better than tamiflu and also targets avian/pandemic strains.
not expecting the stock to double on this but it does show consistent delivery when it comes to anti-virlas from vertex so confidence in the molecule would be high
Between the cost of the vaginal mesh fiasco and faulty hip replacements, J&J might not be around much longer as it exists presently.
The vaginal mesh currently has 2,100 suits pending - and the first one just settled north of 3 million excluding punitive damages which are still under consideration. This of itself is a 7 billion dollar potential - and could go as high as 28 billion.
The faulty hip implants - I believe there is more there but I don't remember the figures off the back of my mind.
I wonder who the insurance carrier is for these divisions respectively...